Prostatic Neoplasms

Oncology·MeSH: Prostatic Neoplasms

Prevalence

256.0 / 100K

Incidence

111.0 / 100K/yr

82 drugs in development·15 companies·37 clinical trials

Drug Pipeline by Phase

Phase 3(39)

Drug	Company
177lu-psma-617	Novartis AG (NVS)
177Lu-PSMA-617	Novartis AG (NVS)
abiraterone	GH Research PLC (GHRS)
abiraterone	CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH)
Abiraterone acetate	Merck & Co., Inc. (MRK)
Abiraterone Acetate	ARS Pharmaceuticals, Inc. (SPRY)
adt	Novartis AG (NVS)
Androgen-deprivation Therapy	Myovant Sciences Ltd. (MYOV)
Apalutamide	Myovant Sciences Ltd. (MYOV)
Apalutamide	ARS Pharmaceuticals, Inc. (SPRY)
Apalutamide 60 mg or 240 mg tablets	KYNTRA BIO INC. (KYNB)
ardt	Novartis AG (NVS)
ARDT	Novartis AG (NVS)
Bicalutamide	ARS Pharmaceuticals, Inc. (SPRY)
Cabazitaxel	Merck & Co., Inc. (MRK)
cetrelimab	GH Research PLC (GHRS)
Conventional NSAA	KYNTRA BIO INC. (KYNB)
Darolutamide	ARS Pharmaceuticals, Inc. (SPRY)
Darolutamide	Merus N.V. (MRUS)
Darolutamide	ELI LILLY & Co (LLY)
Enzalutamide	Myovant Sciences Ltd. (MYOV)
Fludrocortisone acetate	Merck & Co., Inc. (MRK)
GnRH	ARS Pharmaceuticals, Inc. (SPRY)
Hydrocortisone	Merck & Co., Inc. (MRK)
JNJ-56021927	ARS Pharmaceuticals, Inc. (SPRY)
jnj-78278343	GH Research PLC (GHRS)
jnj-86974680	GH Research PLC (GHRS)
jnj-87189401	GH Research PLC (GHRS)
LHRHa	Myovant Sciences Ltd. (MYOV)
LHRHA	KYNTRA BIO INC. (KYNB)
New Formulation of Niraparib and Abiraterone Acetate	ARS Pharmaceuticals, Inc. (SPRY)
New Formulation of Niraparib and Abiraterone Acetate	Janux Therapeutics, Inc. (JANX)
niraparib	GH Research PLC (GHRS)
Niraparib	Myovant Sciences Ltd. (MYOV)
Niraparib	Janux Therapeutics, Inc. (JANX)
Olaparib	Merck & Co., Inc. (MRK)
Opevesostat	Merck & Co., Inc. (MRK)
pasritamig	GH Research PLC (GHRS)
Standard Adjuvant Endocrine Therapy	PFIZER INC (PFE)

Phase 2(6)

Drug	Company
68ga-psma-11	Novartis AG (NVS)
68Ga-PSMA-11	Novartis AG (NVS)
ADT	Novartis AG (NVS)
bridging therapy	GH Research PLC (GHRS)
Flotufolastat F18	Valneva SE (VALN)
novel hormonal therapy	PFIZER INC (PFE)

Phase 1(17)

Drug	Company
Apalutamide	Janux Therapeutics, Inc. (JANX)
BI 836845	KYNTRA BIO INC. (KYNB)
Bridging Therapy	Janux Therapeutics, Inc. (JANX)
Enzalutamide	Janux Therapeutics, Inc. (JANX)
jnj-101556143	GH Research PLC (GHRS)
jnj-69086420	GH Research PLC (GHRS)
jnj-75229414	GH Research PLC (GHRS)
JNJ-75229414	KYNTRA BIO INC. (KYNB)
JNJ-75229414	Merus N.V. (MRUS)
JNJ-75229414	Filana Therapeutics Inc. (FLNA)
JNJ-75229414	Janux Therapeutics, Inc. (JANX)
JNJ-78278343	Janux Therapeutics, Inc. (JANX)
jnj-95298177	GH Research PLC (GHRS)
JNJ-95298177	Janux Therapeutics, Inc. (JANX)
LHRH agonist/antagonist	ELI LILLY & Co (LLY)
QLH12016	KYNTRA BIO INC. (KYNB)
TVB-2640	KYNTRA BIO INC. (KYNB)

Unknown(1)

Drug	Company
Abiraterone acetate	Janux Therapeutics, Inc. (JANX)

N/A(1)

Drug	Company
GLP-1 receptor agonist	ELI LILLY & Co (LLY)

Phase 1/Phase 2(2)

Drug	Company
[177lu]lu-nns309	Novartis AG (NVS)
Enzalutamide	Arcus Biosciences, Inc. (RCUS)

Phase 2/Phase 3(1)

Drug	Company
[18f]ctt1057	Novartis AG (NVS)

Phase 4(15)

Drug	Company
abiraterone	PFIZER INC (PFE)
Abiraterone	KYNTRA BIO INC. (KYNB)
Abiraterone acetate	KYNTRA BIO INC. (KYNB)
Abiraterone acetate 250 mg or 500 mg tablets	KYNTRA BIO INC. (KYNB)
androgen deprivation therapy	GH Research PLC (GHRS)
Androgen receptor inhibitor	KYNTRA BIO INC. (KYNB)
Androgen Receptor Pathway Inhibitors	KYNTRA BIO INC. (KYNB)
Androgen Receptor Signal Inhibitor	KYNTRA BIO INC. (KYNB)
Androgen Receptor Signalling Inhibitor	KYNTRA BIO INC. (KYNB)
androgen-deprivation therapy	GH Research PLC (GHRS)
Androgen-deprivation Therapy	Janux Therapeutics, Inc. (JANX)
Apalutamide	KYNTRA BIO INC. (KYNB)
Bicalutamide	KYNTRA BIO INC. (KYNB)
Darolutamide	KYNTRA BIO INC. (KYNB)
Enzalutamide	Royalty Pharma plc (RPRX)

Compare drugs

177lu-psma-617 vs abiraterone 177lu-psma-617 vs Abiraterone acetate 177lu-psma-617 vs adt

Frequently asked questions

How many drugs are in development for Prostatic Neoplasms?

BioSniper tracks 82 drugs in development for Prostatic Neoplasms across 15 companies.

How many clinical trials target Prostatic Neoplasms?

There are 37 clinical trials targeting Prostatic Neoplasms tracked by BioSniper.

What is the prevalence of Prostatic Neoplasms?

The estimated prevalence of Prostatic Neoplasms is approximately 256.0 per 100,000 population.

Deep-dive into Prostatic Neoplasms

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis